Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
about
An update on vaccine therapy and other immunotherapeutic approaches for glioblastomaProgress and problems with the use of suicide genes for targeted cancer therapyB cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancerEvolution of malignant glioma treatment: from chemotherapy to vaccines to viruses.Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model studyPhase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.Proposed mechanisms of action for prostate cancer vaccines.Three steps to breaking immune tolerance to lymphoma: a microparticle approach.Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response.Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastomaIntraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer.Adenovirus: the first effective in vivo gene delivery vectorSwitching a replication-defective adenoviral vector into a replication-competent, oncolytic adenovirus.Glioma virus therapies between bench and bedside.The spectrum of vaccine therapies for patients with glioblastoma multiformeTargeting the fetal acetylcholine receptor in rhabdomyosarcoma.Can anesthetic techniques or drugs affect cancer recurrence in patients undergoing cancer surgery?Integrating Immunotherapies in Prostate Cancer.Self-assembled autophagy-inducing polymeric nanoparticles for breast cancer interference in-vivo.Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant gliomaTherapeutic endoscopic ultrasonography: intratumoral injection for pancreatic adenocarcinoma.Prostate cancer vaccines: Update on clinical development.Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine.Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.Immunotherapy and gene therapy as novel treatments for cancer.Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.Immunotherapy for Prostate Cancer: Where We Are Headed.The effect of propofol and sevoflurane on cancer cell, natural killer cell, and cytotoxic T lymphocyte function in patients undergoing breast cancer surgery: an in vitro analysis.Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells.Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas.Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.Interleukin-17 facilitates the immune suppressor capacity of high-grade glioma-derived CD4 (+) CD25 (+) Foxp3 (+) T cells via releasing transforming growth factor beta.Oncolytic virus and PD-1/PD-L1 blockade combination therapyPerspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer
P2860
Q27024830-3689782D-187C-4DCA-B843-D509DCEB8579Q28262370-F20BB708-9179-44C0-B8F9-1BD1D4E2C96BQ33721433-45C5A147-8A41-4F3F-A0AA-B1B27114E5A2Q33923950-2726A044-AE2D-4957-B51E-8D51689B9748Q33933202-DEB68209-887C-4C93-9558-A22117406302Q34208293-9AB6EA6E-341D-4242-900C-60BAF0DDF10FQ34859794-9DBA8BFA-0027-42FE-A726-B29D25FD279FQ35174754-E49099F3-1828-47A4-A663-04DEDED08B00Q35328686-706824E9-B1CB-4127-B1E2-70B535A2D543Q36659314-E3A767CC-691C-435B-AC59-DF09B56C5341Q36811505-D6AF1BE5-C3E6-4D6B-86A3-35DA95AD52EFQ37347492-6F733741-A283-4379-B733-6D254FA284A3Q37508260-934F93BA-FB68-4301-90C8-8E872FE758B6Q37547783-E4344902-3655-4731-92BB-C82EF61C77FEQ37580510-F8D12CC5-03A1-4840-BC90-6A2C9BDEC4CAQ38035788-2E0F413A-4920-40E7-AB18-751250DBD684Q38066542-85BB4066-1C7A-461A-B185-2A37AE2E6539Q38106658-AB876316-A94B-4777-81A6-203DAD16366DQ38567067-ED67DA50-BB02-4436-B674-50B48EBC9A09Q38897962-516AEA07-DAF2-4553-B99D-80F2A089E5C2Q38912327-2A4A8794-F04D-441E-BAB3-54F6C0F74D4DQ39769809-D72190C9-1DC9-4DE3-AD9E-DD3FD4C4E6C7Q41220895-E36F256C-422E-426F-A48B-F46CA1EB714BQ41699782-1E2DB001-364E-4B6E-9387-E71ED1C37BDDQ42153454-7601E954-4A68-4A91-B457-C066336C49DDQ45875535-0E945611-C0A9-46D7-81F2-C4C36FA2D093Q47827127-74F73A0A-5842-401B-BF2E-A3D4DF3A0A43Q48176349-218C6360-B5B0-4939-87D7-8FBEC7018AE1Q49270417-80F7A0A5-5CC1-47AD-9C89-CD50AC834BC0Q50545957-711CDE93-57A7-4DA4-801C-64F8A362006AQ52145215-17E10CA8-6A7F-4678-B6C8-4E103D9CAA1DQ52650848-4C0ED3D1-0DDA-4415-A463-4A8E8BF3B1AAQ52746279-4F422227-F582-4DD3-8C00-1F114B7DFAC4Q55460935-6BFD2CF1-F76B-405F-A9AA-FC32002E5E92Q57174025-EF49F353-8518-4E81-8621-BA26C466D19DQ58699214-99EB54AA-E066-4A8D-9B45-D942BDC3AF31
P2860
Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
@en
Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
@nl
type
label
Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
@en
Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
@nl
prefLabel
Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
@en
Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
@nl
P2093
P2860
P356
P1476
Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
@en
P2093
Brian W Guzik
Estuardo Aguilar-Cordova
Laura K Aguilar
P2860
P304
P356
10.1002/JCB.23126
P577
2011-08-01T00:00:00Z